PL2968269T3 - Sposób przygotowywania agonistów beta-3 i produktów pośrednich - Google Patents

Sposób przygotowywania agonistów beta-3 i produktów pośrednich

Info

Publication number
PL2968269T3
PL2968269T3 PL14768236T PL14768236T PL2968269T3 PL 2968269 T3 PL2968269 T3 PL 2968269T3 PL 14768236 T PL14768236 T PL 14768236T PL 14768236 T PL14768236 T PL 14768236T PL 2968269 T3 PL2968269 T3 PL 2968269T3
Authority
PL
Poland
Prior art keywords
agonists
intermediates
preparing beta
beta
preparing
Prior art date
Application number
PL14768236T
Other languages
English (en)
Inventor
Feng Xu
Zhuqing Liu
Richard Desmond
Jeonghan Park
Alexei Kalinin
Birgit Kosjek
Hallena Strotman
Hongmei Li
Johannah MONCECCHI
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51580798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2968269(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of PL2968269T3 publication Critical patent/PL2968269T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10Nitrogen as only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL14768236T 2013-03-15 2014-03-12 Sposób przygotowywania agonistów beta-3 i produktów pośrednich PL2968269T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791247P 2013-03-15 2013-03-15
EP14768236.3A EP2968269B1 (en) 2013-03-15 2014-03-12 Process for preparing beta 3 agonists and intermediates
PCT/US2014/023858 WO2014150639A1 (en) 2013-03-15 2014-03-12 Process for preparing beta 3 agonists and intermediates

Publications (1)

Publication Number Publication Date
PL2968269T3 true PL2968269T3 (pl) 2020-03-31

Family

ID=51580798

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14768236T PL2968269T3 (pl) 2013-03-15 2014-03-12 Sposób przygotowywania agonistów beta-3 i produktów pośrednich

Country Status (16)

Country Link
US (7) US10287289B2 (pl)
EP (2) EP2968269B1 (pl)
JP (1) JP6383403B2 (pl)
CY (1) CY1122690T1 (pl)
DK (1) DK2968269T3 (pl)
ES (1) ES2746801T3 (pl)
HR (1) HRP20191546T1 (pl)
HU (1) HUE045260T2 (pl)
LT (1) LT2968269T (pl)
ME (1) ME03506B (pl)
PL (1) PL2968269T3 (pl)
PT (1) PT2968269T (pl)
RS (1) RS59402B1 (pl)
SI (1) SI2968269T1 (pl)
SM (1) SMT201900508T1 (pl)
WO (1) WO2014150639A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150087832A1 (en) 2011-10-27 2015-03-26 Merck Sharp & Dohme, Corp. Process for making beta 3 agonists and intermediates
WO2013062878A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 angonists and intermediates
PL2968269T3 (pl) * 2013-03-15 2020-03-31 Merck Sharp & Dohme Corp. Sposób przygotowywania agonistów beta-3 i produktów pośrednich
CN104496875B (zh) * 2014-12-12 2017-09-08 常州大学 2‑烯丙基‑2‑甲醛基‑n‑苯基吡咯碄的合成方法
EP4410295A3 (en) 2017-06-06 2024-10-16 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
CN110869053A (zh) 2017-06-06 2020-03-06 乌洛万特科学有限公司 给药维贝隆以治疗膀胱过度活动症
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
SG11202010683PA (en) 2018-05-23 2020-12-30 Urovant Sciences Gmbh Use of vibegron to treat pain associated with irritable bowel syndrome
KR102940911B1 (ko) 2018-12-05 2026-03-17 유로반트 사이언시즈 게엠베하 과민성 방광 증상의 치료를 위한 비베그론
EP3941473A1 (en) 2019-03-18 2022-01-26 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
US20240050457A1 (en) 2020-12-22 2024-02-15 Urovant Sciences Gmbh Methods of monitoring digoxin with concomitant use of vibegron to treat overactive bladder
WO2022175848A1 (en) 2021-02-16 2022-08-25 Urovant Sciences Gmbh Methods of treating heart failure with vibegron
CN113816917B (zh) * 2021-11-19 2022-02-18 奥锐特药业(天津)有限公司 一种维贝格龙中间体的制备方法
CN115850286B (zh) * 2022-12-05 2023-08-22 奥锐特药业(天津)有限公司 一种维贝格龙中间体及其制备方法
CN117467628B (zh) * 2023-09-18 2024-04-16 长兴制药股份有限公司 一种酮还原酶及其制备高光学纯度β-3肾上腺素能激动剂中间体的方法
WO2025262600A1 (en) 2024-06-17 2025-12-26 Urovant Sciences Gmbh Crystalline form of vibegron hemihydrate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
KR101586503B1 (ko) 2007-09-13 2016-01-18 코덱시스, 인코포레이티드 아세토페논의 환원을 위한 케토리덕타제 폴리펩티드
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
CN102186972B (zh) 2008-08-29 2014-08-20 科德克希思公司 用于立体选择性生产(4s)-3-[(5s)-5-(4-氟苯基)-5-羟基戊酰基]-4-苯基-1,3-噁唑烷-2-酮的酮还原酶多肽
NZ599233A (en) 2009-10-07 2013-04-26 Merck Sharp & Dohme Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
JP5812500B2 (ja) * 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ3アドレナリン作動性受容体アゴニスト
WO2013062878A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 angonists and intermediates
US20150087832A1 (en) 2011-10-27 2015-03-26 Merck Sharp & Dohme, Corp. Process for making beta 3 agonists and intermediates
EP2780448B1 (en) * 2011-11-18 2019-09-11 Codexis, Inc. Biocatalysts for the preparation of hydroxy substituted carbamates
PL2968269T3 (pl) * 2013-03-15 2020-03-31 Merck Sharp & Dohme Corp. Sposób przygotowywania agonistów beta-3 i produktów pośrednich

Also Published As

Publication number Publication date
PT2968269T (pt) 2019-10-08
US20240300960A1 (en) 2024-09-12
EP3597737A1 (en) 2020-01-22
ME03506B (me) 2020-04-20
LT2968269T (lt) 2019-10-25
JP6383403B2 (ja) 2018-08-29
EP2968269A1 (en) 2016-01-20
ES2746801T3 (es) 2020-03-06
SMT201900508T1 (it) 2019-11-13
US11091493B2 (en) 2021-08-17
SI2968269T1 (sl) 2019-12-31
US10696681B2 (en) 2020-06-30
US20190194211A1 (en) 2019-06-27
RS59402B1 (sr) 2019-11-29
EP2968269A4 (en) 2016-12-28
JP2016515117A (ja) 2016-05-26
DK2968269T3 (da) 2019-10-07
US12180219B2 (en) 2024-12-31
US20250304588A1 (en) 2025-10-02
WO2014150639A1 (en) 2014-09-25
US20200392141A1 (en) 2020-12-17
CY1122690T1 (el) 2021-03-12
US10287289B2 (en) 2019-05-14
US20220073523A1 (en) 2022-03-10
US20170145014A1 (en) 2017-05-25
US11649243B2 (en) 2023-05-16
EP2968269B1 (en) 2019-07-10
HUE045260T2 (hu) 2019-12-30
HRP20191546T1 (hr) 2019-11-29
US20240300955A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
PL2968269T3 (pl) Sposób przygotowywania agonistów beta-3 i produktów pośrednich
IL264500B (en) Measurement of multiple patterning parameters
IL269227B (en) Solid forms of treprostinil
HRP20190233T1 (hr) Postupci i intermedijeri za dobivanje inhibitora jak
IL246002A0 (en) Novel methods
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
DK3015467T3 (da) Morpholino-oligonukleotidfremstillingsfremgangsmåde
LT3057586T (lt) Bromodomeno inhibitoriai
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
PL2941442T3 (pl) Sposób wytwarzania mikrofibrylarnej celulozy
HUE036383T2 (hu) Bevonási eljárás
DK3010352T3 (da) Fremgangsmåde til fremstilling af fodertilsætning
LT3038654T (lt) Naujas panaudojimas
PT2953948T (pt) Antagonistas de integrina fluorada
LT3007726T (lt) Tautopatijos gydymo būdai
DK2970235T3 (da) Nye inhibitorer
DK2943561T3 (da) Fotobioreaktor
LT3369724T (lt) Iopamidolio gamybos būdas
BR112015021083A2 (pt) método
EP2945942A4 (en) Voriconazole IMMUNOASSAY
FR3001759B1 (fr) Rouge aubagee de turbomachine
PL2860256T3 (pl) Sposób wytwarzania L-aminokwasów
BR112015029076A2 (pt) método
FI20135341L (fi) Menetelmä biopolttoaineen valmistamiseksi ja biopolttoaineen käyttö